StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.30−0.48 (-4.91%)

Close on Nov 18, 2026Market cap $534.16MP/E –Yield –

Climb Bio operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Climb Bio's operating income for the twelve months ending Jun 30, 2026 was -$64.76M. For fiscal 2025 it was -$67.88M. The highest annual figure on record is -$20.93M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$67.88M–
FY2024Dec 31, 2024-$82.02M–
FY2023Dec 31, 2023-$40.28M–
FY2022Dec 31, 2022-$45.14M–
FY2021Dec 31, 2021-$35.67M–
FY2020Dec 31, 2020-$20.93M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$15.36M–
Q1 FY2026Mar 31, 2026-$15.21M–
Q4 FY2025Dec 31, 2025-$19.30M–
Q3 FY2025Sep 30, 2025-$14.89M–
Q2 FY2025Jun 30, 2025-$10.68M–
Q1 FY2025Mar 31, 2025-$23.02M–
Q4 FY2024Dec 31, 2024-$10.91M–
Q3 FY2024Sep 30, 2024-$11.73M–
Q2 FY2024Jun 30, 2024-$56.37M–
Q1 FY2024Mar 31, 2024-$3.01M–
Q4 FY2023Dec 31, 2023-$5.12M–
Q3 FY2023Sep 30, 2023-$5.00M–
Q2 FY2023Jun 30, 2023-$6.71M–
Q1 FY2023Mar 31, 2023-$23.44M–
Q4 FY2022Dec 31, 2022-$9.55M–
Q3 FY2022Sep 30, 2022-$8.75M–
Q2 FY2022Jun 30, 2022-$13.70M–
Q1 FY2022Mar 31, 2022-$13.13M–
Q4 FY2021Dec 31, 2021-$10.70M–
Q3 FY2021Sep 30, 2021-$9.38M–
Q2 FY2021Jun 30, 2021-$8.71M–
Q1 FY2021Mar 31, 2021-$6.88M–
Q4 FY2020Dec 31, 2020-$15.11M–
Q3 FY2020Sep 30, 2020-$2.26M–
Q2 FY2020Jun 30, 2020-$1.61M–

More Climb Bio figures

See a number that looks wrong?